Fig. 1From: Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre studyFlow chart of the study. M, month; SAE, serious adverse event; AE, adverse event; TCZ SC, tocilizumab subcutaneousBack to article page